1. Home
  2. PRT vs RNTX Comparison

PRT vs RNTX Comparison

Compare PRT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$3.87

Market Cap

47.7M

Sector

Energy

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

BUY

Current Price

$1.53

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
PRT
RNTX
Founded
2017
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
38.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRT
RNTX
Price
$3.87
$1.53
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
28.0K
184.8K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
10.91%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$6,009,225.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$1.04
52 Week High
$4.63
$3.50

Technical Indicators

Market Signals
Indicator
PRT
RNTX
Relative Strength Index (RSI) 43.71 58.01
Support Level $3.83 $1.34
Resistance Level $3.95 $1.58
Average True Range (ATR) 0.06 0.10
MACD -0.00 0.01
Stochastic Oscillator 8.33 87.50

Price Performance

Historical Comparison
PRT
RNTX

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: